|Mr. Alain Moussy MBA||Co-Founder, Chairman, Chief Exec. Officer and Scientific Director||N/A||N/A||N/A|
|Mr. Denis Gicquel||Deputy Chief Exec. Officer and Head Pharmacist||89k||N/A||N/A|
|Mr. Laurent Guy MBA||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Albert Ahn D.V.M.||Pres of USA Operations||N/A||N/A||N/A|
AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. The companys lead compound is the Masitinib, a tyrosine kinase inhibitor, which has completed Phase II trials, as well as in Phase III trials for the treatment of oncology, inflammatory, multiple sclerosis, Alzheimer's, and amyotrophic lateral sclerosis diseases. It also develops other compounds, such as KIT816 for the treatment of mastocytosis, seminoma, and acute myeloid leukemia; and Syk for treating rheumatoid arthritis/B-cell lymphoma. In addition, the company offers Masitinib for the treatment of oncology and inflammatory diseases for dogs and cats. It markets its Masitinib under the Masivet brand in Europe; and Kinavet brand in the United States. The company serves hospitals and specialist physicians. The company was founded in 2001 and is headquartered in Paris, France.
AB Science S.A.’s ISS Governance QualityScore as of August 1, 2017 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 10; Compensation: 10.